Pancreas Cancer Discussion Page:
An Unmoderated Forum
*
 
Support pancreas research*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER

Pancreas Cancer

ARQ 501 was posted 01/31/2006 04:47 pm by Carol (Texas)
E-mail Address:

Message Text
Here's the explanation I have found for how this drug works: 'ArQule’s first clinical-stage compound, ARQ 501, is an E2F modulator that has demonstrated in preclinical studies potency and selectivity in the activation of faulty cellular checkpoint machinery in cancer cells. ARQ 501 activates E2F-mediated checkpoints leading to selective apoptosis (programmed death) of cancer cells. The compound also has demonstrated anti-cancer activity in mice when applied as both a single agent and in combination with certain chemotherapeutics.' The short explanation is that somehow it turns on a sequence which causes the tumor cells (and only the tumor cells) to commit suicide. That's the theory. How well it will work on PC cells, which tend to be 'smarter' than other cancer cells, who knows? There are trials using this drug in several places -- I know that in addition to Mary Crowley in Dallas, MDAnderson has some trials.

Reply to this message | Return to Main Message List
Responses

*DISCLAIMER: This page is an unmoderated forum, and the opinions expressed herein do not necessarily reflect the viewpoint of The Johns Hopkins Medical Institutions. Patients are advised to consult their personal physicians before making any medical decisions.
FULL DISCLAIMER


Pancreas Home | Surgical | Medical | Basic Sci | Docs | Registry | FAQ | Appts | Chat

Feedback | Pathology Home | Oncology Center Home | Search
Copyright © 2020 The Johns Hopkins University, Baltimore, Maryland
Last Modified: 11/11/2002 10:50 am